In 2019 the NHS agreed to fund the treatment, Luxturna, the first in a new generation of gene therapies for conditions causing blindness. It costs about £600,000 per patient to treat both eyes, though the NHS has agreed a confidential discount with the makers Novartis.

Categories:

Tags:

Comments are closed